Healios K.K. (OTCMKTS:HLOSF – Get Free Report) is expected to issue its resultson Wednesday, August 12th. Analysts expect Healios K.K. to announce earnings of ($0.0149) per share and revenue of $0.1090 million for the quarter.
Healios K.K. Stock Performance
Shares of OTCMKTS HLOSF opened at $1.80 on Wednesday. Healios K.K. has a one year low of $1.80 and a one year high of $4.45. The business’s 50-day moving average price is $1.80 and its two-hundred day moving average price is $2.09.
About Healios K.K.
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
See Also
- Five stocks we like better than Healios K.K.
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
